Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

HOPE Asia Network consensus recommendations on home blood pressure monitoring

12 Apr 2018
Non-communicable diseases have been recognized by the World Health Organization (WHO) as reaching epidemic proportions. As a result, the WHO has set a goal of reducing the global incidence of cardiovascular disease (CVD) by 25% by 2025.

“One of the key targets [of the WHO] is improving the treatment of hypertension, because it is the most important risk factor for CVD,” commented Professor Sungha Park, lead author of the HOPE Asia Network’s consensus recommendations on home blood pressure monitoring (HBPM). These recommendations provide clear guidance to clinicians in the region on how to incorporate HBPM into routine clinical practice, and thus improve hypertension management.

HBPM is increasingly being recognized as an accurate adjunct to clinic blood pressure (BP) measurement for the diagnosis and management of hypertension, and several international guidelines have now incorporated HBPM into their recommendations. In particular, HBPM reduces the risk of patients with masked hypertension or white-coat hypertension being misdiagnosed through clinic assessments alone, and has shown good predictive power for cardiovascular events.

“HBPM is a better predictor of cardiovascular outcome than office BP. When there is a discrepancy of diagnosis between office and home BP, a home BP-based diagnosis should have priority and, when possible, be confirmed by ambulatory blood pressure monitoring. (Class I, Level of Evidence B)”.
Despite the growing recognition of the value of HBPM, its uptake in Asia has been limited by barriers, including physician inertia and access to validated HBPM devices. The HOPE Asia Network consensus considers these regional challenges in their recommendations to provide implementable guidance on how HBPM can be utilized in the day-to-day management of hypertension.

Professor Park believes that the HOPE Asia Network recommendations will encourage physicians throughout the region to integrate HBPM into the primary care setting. The active monitoring that accompanies HBPM is also an effective method of improving treatment adherence, which can translate into further incremental improvements in BP control.

“HBPM can improve adherence when combined with active intervention, and thus improve BP control compared with current standard care alone (Class I, Level of Evidence B).”

Greater uptake of HBPM is expected to help the Asia-Pacific region meet the WHO’s CVD targets by improving BP management practices and reducing the number of cardiovascular events. Increased uptake of HBPM will also assist the HOPE Asia Network’s efforts to better understand BP control and the prevalence of masked, white-coat and morning hypertension in the region. This enhanced understanding can then be used as a springboard towards further studies of CVD, to better elucidate the characteristics of Asian hypertension patients and the benefits of HBPM.

Reference: Park S, et al. J Hum Hypertens 2018 Jan 31 [Epub ahead of print]
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.